Mitapivat vs Mitapivat (Aqvesme)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Transfusion-Dependent Beta Thalassemia

Shared mechanism: Pyruvate kinase · full Transfusion-Dependent Beta Thalassemia pipeline

Mitapivat · Pyrukynd

Marketed by AGIOS PHARMACEUTICALS, INC. and partners

Phase 3 in Transfusion-Dependent Beta Thalassemiasmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: June 2029 · NCT07506863 (registry estimate)

No aligned efficacy figure on record for this race.

Mitapivat (Aqvesme)

Marketed by AGIOS PHARMACEUTICALS, INC.

Approved in Transfusion-Dependent Beta Thalassemiasmall molecule
Partial signal

NCT04770779 · Phase 3 · active, not recruiting

The study was randomized, quadruple-blind, and placebo-controlled, with 258 participants, and its clinical primary endpoint was met in favor of mitapivat. However, no primary-endpoint power calculation is reported in the provided record, so the evidence is graded moderate rather than strong.

Reported efficacy

Double-blind Period: Percentage of Participants Who Achieved Transfusion Reduction Response (TRR) (Double-blind Period: Baseline through Week 48): Transfusion reduction response in the double-blind period (baseline through Week 48), mitapivat vs placebo: 30.4% vs 12.6%, common risk difference 17.6 percentage points (95% CI 8.0 to 27.2), p=0.0003 (CT.gov posted results). (met)

Result source: NCT04770779

Results for Transfusion-Dependent Beta Thalassemia

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Mitapivat: no structured comparison results are available for Transfusion-Dependent Beta Thalassemia.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Mitapivat (Aqvesme)
Transfusion reduction response in the double-blind period (baseline through Week 48), mitapivat vs placebo: 30.4% vs 12.6%, common risk difference 17.6 percentage points (95% CI 8.0 to 27.2), p=0.0003 (CT.gov posted results). NCT04770779 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result
Hemoglobin response from Week 12 through Week 24 in the double-blind period, mitapivat vs placebo: 42.3% vs 1.6%, difference 40.9 percentage points (95% CI 32.0 to 49.8), p<0.0001 (CT.gov posted results). NCT04770753 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Mitapivat's landscape · Mitapivat (Aqvesme)'s landscape